Gilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study

MT Newswires Live

Mar 12, 2025

Gilead Sciences (GILD) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.

The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.

The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.

The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.

Gilead shares were down 2% in recent trading.

Price: 114.77, Change: -2.44, Percent Change: -2.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2518778375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518778375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2518778375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-12 02:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518778375","market":"sh","top_or_hot":-1,"title":"Gilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study","media":"MT Newswires Live","content":"<html><body><p> Gilead Sciences (GILD) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.</p><p>The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.</p><p>The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.</p><p>The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.</p><p>Gilead shares were down 2% in recent trading.</p><p>Price: 114.77, Change: -2.44, Percent Change: -2.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-12 02:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Gilead Sciences (GILD) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.</p><p>The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.</p><p>The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.</p><p>The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.</p><p>Gilead shares were down 2% in recent trading.</p><p>Price: 114.77, Change: -2.44, Percent Change: -2.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066053197.SGD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2518778375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518778375","pubTimestamp":1741716420,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gilead Sciences  said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.Gilead shares were down 2% in recent trading.Price: 114.77, Change: -2.44, Percent Change: -2.08","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4583":"猴痘概念","BK4532":"文艺复兴科技持仓","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4566":"资本集团","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4578":"CAR-T","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","GILD":"吉利德科学","BK4568":"美国抗疫概念","LU0058720904.USD":"联博国际健康护理基金A","BK4550":"红杉资本持仓","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"吉利德科学每年一次的HIV预防治疗在研究中安全、耐受性良好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"Gilead Sciences (GILD) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.Gilead shares were down 2% in recent trading.Price: 114.77, Change: -2.44, Percent Change: -2.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}